It is frustrating......but just imagine 6 weeks from now if Parsons, Rigby & ONC have still not landed a deal/buyout. Noteable has mentioned that BP likes to wrap up M&A activities by the end of the calendar year in which they started. I think it's very safe to say PFE has known since early Q3 what Oncy has and negotiations are ongoing & in fact probably greatly sped up due to the miraculous Goblet data. PFE has to have palpable pressure to nail this down, because, as many have mentioned, Roche has all the evidence they need. Maybe the strict packaging of the mBC & Panc indications together has caused some delays and forced negotiations to backtrack some. I mean BP is now gonna be forced to pay double pretty much. Good for us...maybe not for PFE. All this to say that the negative sentiment will grow tenfold if this team can't sell a multi ph3 biotech and it may suggest that maybe BP aren't gonna spend the $$$.